Skip to main content

Advertisement

SpringerLink
Log in

IMMUNOTHERAPY

PD-1+ Treg cells: a foe in cancer immunotherapy?

  • News & Views
  • Published:

From Nature Immunology

View current issue Submit your manuscript

The mechanisms that drive responses to PD-1-blocking immunotherapy in some but not all patients have been puzzling. A new study suggests that the balance of PD-1 expression levels between CD8+ T cells and Treg cells might provide an answer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Levels of PD-1 expression by Treg and CD8+ T cells determine the efficacy of PD-1 immunotherapy.

Debbie Maizels/Springer Nature

References

  1. Kumagai, S. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0769-3 (2020).

  2. Miyara, M. et al. Immunity 30, 899–911 (2009).

    Article  CAS  Google Scholar 

  3. Wing, J. B., Tanaka, A. & Sakaguchi, S. Immunity 50, 302–316 (2019).

    Article  CAS  Google Scholar 

  4. Hsieh, C.-S. et al. Immunity 21, 267–277 (2004).

    Article  CAS  Google Scholar 

  5. Fife, B. T. et al. J. Exp. Med. 203, 2737–2747 (2006).

    Article  CAS  Google Scholar 

  6. Zhang, B., Chikuma, S., Hori, S., Fagarasan, S. & Honjo, T. Proc. Natl Acad. Sci. USA 113, 8490–8495 (2016).

    Article  CAS  Google Scholar 

  7. Francisco, L. M. et al. J. Exp. Med. 206, 3015–3029 (2009).

    Article  CAS  Google Scholar 

  8. Patsoukis, N. et al. Nat. Commun. 6, 6692 (2015).

    Article  CAS  Google Scholar 

  9. Shi, L. Z. et al. J. Exp. Med. 208, 1367–1376 (2011).

    Article  CAS  Google Scholar 

  10. Haxhinasto, S., Mathis, D. & Benoist, C. J. Exp. Med. 205, 565–574 (2008).

    Article  CAS  Google Scholar 

  11. Delgoffe, G. M. et al. Immunity 30, 832–844 (2009).

    Article  CAS  Google Scholar 

  12. Ali, K. et al. Nature 510, 407–411 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Institutes of Health awards RO1CA212605, RO1CA238263 and RO1CA229784 (V.A.B.).

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Halil-Ibrahim Aksoylar & Vassiliki A. Boussiotis

  2. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Halil-Ibrahim Aksoylar & Vassiliki A. Boussiotis

Authors
  1. Halil-Ibrahim Aksoylar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vassiliki A. Boussiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vassiliki A. Boussiotis.

Ethics declarations

Competing interests

V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors declare no other competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aksoylar, HI., Boussiotis, V.A. PD-1+ Treg cells: a foe in cancer immunotherapy?. Nat Immunol 21, 1311–1312 (2020). https://doi.org/10.1038/s41590-020-0801-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-020-0801-7

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation